AbbVie Files for EMA Approval of New Subcutaneous Crohn's Injection Option

AbbVie has submitted an application to the European Medicines Agency (EMA) for a subcutaneous induction regimen of its drug SKYRIZI for Crohn's disease, based on positive Phase 3 AFFIRM trial results. This filing aims to provide a less invasive, subcutaneous injection option for induction therapy, offering greater flexibility for eligible patients.